Five Prime Therapeutics (FPRX) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($2.1 million) and the uptick to downtick ratio was 0.57. The transaction value on upticks was $2.79 million and on downticks, the transaction value was $4.9 million. The transaction value of block trades during downticks was $1.76 million. The money flow was negative ($1.76 million), indicating the traders were booking profit on the price strength. Five Prime Therapeutics (FPRX) rose $0.06 at $43.76, during intraday Thursday , a rise of 0.14% over the previous days close.
Five Prime Therapeutics (FPRX) : The consensus price target for Five Prime Therapeutics (FPRX) is $46 for the short term with a standard deviation of $3.92. The most optimist securities analyst among the 4 who monitor the stock believes that the stock can reach $50, however, the pessimist price target for the company is $41. The stock has recorded a 20-day Moving Average of 6.42% and the 50-Day Moving Average is 2.71%.
Five Prime Therapeutics (NASDAQ:FPRX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $43.65 and $42.92 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $44.32. The buying momentum continued till the end and the stock did not give up its gains. It closed at $43.92, notching a gain of 0.50% for the day. The total traded volume was 415,270 . The stock had closed at $43.70 on the previous day.
Five Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Companys product candidates include FPA008, FPA144 and FP-1039/GSK3052230. FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R), that the Company is developing in rheumatoid arthritis. FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b), which the Company is developing to treat patients with gastric cancer. FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs), involved in cancer cell proliferation and new blood vessel formation. Its partner, GlaxoSmithKline is developing FP-1039/GSK3052230 to treat patients with squamous non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma.